InflaRx N.V.

InflaRx N.V. reported a net loss of €45.6 million for FY 2025, an improvement from €46.1 million in FY 2024, driven by reduced R&D expenses (€25.7 million vs. €35.4 million) and marketing/sales costs (€4.5 million vs. €6.8 million), offset by higher cost of sales (€7.3 million vs. €3.3 million) from inventory write-downs. Revenue fell to €29K from €166K, reflecting scaled-back commercialization of GOHIBIC (vilobelimab) post-strategic refocus. Operating loss narrowed to €48.3 million from €53.0 million. Loss per share improved to €0.68 from €0.78 on 67.3 million weighted average shares. Cash and equivalents decreased to €16.0 million from €18.4 million, with net cash used in operations at €35.3 million (vs. €48.6 million). Financial assets stood at €30.7 million. The company prioritized izicopan development, reducing GOHIBIC efforts, with cash runway into mid-2027 under current plans. Total tax loss carryforwards reached €324.5 million, unused at €257.7 million for corporate tax.

Key Takeaways